rethinkTHC Search
Menu
Study breakdown

Leading researcher describes the expanded endocannabinoidome as a platform for non-psychoactive cannabinoid therapies and gut-brain connections

ReviewModerate evidence
The takeaway

The endocannabinoidome, an expanded network of endocannabinoid-like mediators and receptors, provides targets for non-psychoactive cannabinoids like CBD and connects to the gut microbiome's role in neuropsychiatric disorders.

Neuroscience researchers, gut-brain axis scientists, CBD researchers

CBD's wide therapeutic window may come from hitting multiple eCBome targets simultaneously

What the researchers found

The endocannabinoidome extends beyond classical CB1/CB2 to include numerous lipid mediators, receptors, and enzymes involved in neuropsychiatric disorders. Non-euphoric plant cannabinoids like CBD have a wide therapeutic window because they hit multiple eCBome targets. The eCBome also connects to the microbiota-gut-brain axis, emerging as important for affective and cognitive functions.

Why it matters

This framework from a leading researcher explains why CBD may help diverse neuropsychiatric conditions and introduces the gut microbiome as a new frontier for understanding cannabinoid therapeutics.

The numbers in context

No specific effect sizes; the review provides a conceptual framework connecting the eCBome, plant cannabinoids, and the gut-brain axis.

How the study worked

Expert review by Vincenzo Di Marzo (a pioneer of endocannabinoid research) covering the eCBome concept, its role in neuropsychiatric disorders, the pharmacology of non-psychoactive cannabinoids, and the gut-brain connection.

What this study cannot tell us

Conceptual review by a single author; many proposed connections are still theoretical; the gut-brain-eCBome axis in humans remains poorly characterized.

How to read the evidence

Expert review from a field pioneer providing conceptual framework rather than new data.

When this study was published

Published in 2020.

The bigger picture

The connection between the endocannabinoidome and gut microbiome opens entirely new avenues for understanding how cannabis and cannabinoids affect mental health, potentially through mechanisms unrelated to traditional brain receptor pharmacology.

Questions still open

  • Can gut microbiome interventions enhance or mimic cannabinoid effects on mental health? Which specific eCBome targets explain CBD's therapeutic effects?

Common questions

What is the endocannabinoidome?
It is an expanded version of the endocannabinoid system that includes not just CB1/CB2 and their ligands, but dozens of related lipid mediators, their receptors, and enzymes. This expanded network helps explain why cannabinoids affect so many different body systems.
How does the gut microbiome connect to cannabinoids?
The endocannabinoidome plays a role in the microbiota-gut-brain axis, a communication system between gut bacteria and the brain. Disruptions in this system are linked to mood and cognitive disorders, and cannabinoids may influence mental health partly through gut-level effects.

Read the original research

The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.

Dialogues in clinical neuroscience, 22(3), 259-269

Citation

Di Marzo, Vincenzo. (2020). The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.. Dialogues in clinical neuroscience, 22(3), 259-269. https://doi.org/10.31887/DCNS.2020.22.3/vdimarzo

Explore the wider topic